Home button for the R&D Pipeline
Pipeline Candidates by Disease
Candidates by sub-disease button

NEGLECTED DISEASE PRODUCT PIPELINE CANDIDATES BY PRODUCT TYPE

vaccine
drugs
diagnostics
vectorcontrol

This page presents in-depth, candidate-level information on the R&D product pipeline for neglected diseases as at October 2015. The pipeline information on this page is presented per product category (vaccines, drugs, diagnostics and vector control products), and is sorted in descending order by number of products per category.  For diseases such as the kinetoplastid infections that are in fact a family of related sub-diseases, clicking on the hyperlinked text for these sub-diseases (e.g. sleeping sickness) will take you to a separate page with pipeline information specific to that disease.

Select the hyperlinked product and disease tiles to go directly to the relevant section of the pipeline. If you would like to jump back to the top of the page, simply click on the floating ‘Back to top’ icon in the bottom right-hand corner of your browser window. If you would like to return to the overview page at any time, there is a link provided at the top of the page.

Vaccines

203
products in
the pipeline
HIV Vaccine
maralia vaccine
Diarrhoeal Diseases Vaccine
TB Vaccine
kinetoplastids Vaccine
Helminth Infections Vaccine
Salmonella Infections Vaccines
bacterialM Vaccine
hip_C vaccine
Trachoma Vaccine
Rheumatic Fever vaccine
Buruli Ulcer Vaccine
HIV
(45 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Ad35-GRIN; MVA.HIV-consv
pSG2.HIVconsv-DNA
University of Oxford
International AIDS Vaccine Initiative (IAVI)
ALVAC (vCP2438) + C gp120/MF59
(HVTN 100)
Sanofi
Novartis
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
GTU-MultiHIV B DNA LIPO-5 French Institute of Health and Medical Research (Inserm)
French National Agency for AIDS Research (ANRS)
HIVIS 03 DNA (TaMoVac) Karolinska Institute
Muhimbili University of Health and Allied Sciences Tanzania
Swedish International Development Cooperation Agency
Walter Reed Army Institute of Research (WRAIR)
LIPO-5 French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Sanofi-Aventis
MVA.HIVA IDT Biologika
University of Oxford
UK Medical Research Council (UK MRC)
University of Nairobi
Kenya AIDS Vaccine Initiative
MVA-CMDR Walter Reed Army Institute of Research   (WRAIR)
pDNA + rTV + MHRP gp145 Chinese Center for Disease Control and Prevention
US MilitaryHIV Research Program (MHRP)
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
Vacc-4x Bionor Pharma ASA
Celgene Corporation
AAV-PG9 International AIDS Vaccine Initiative (IAVI)
National Institute of Allergy and Infectious Diseases (NIAID)
Children’s Hospital of Philadelphia
Ad4-mgag + Ad4-EnvC150 + AIDSVAX B/E
(HVTN 110)
PaxVax Inc
Global Solutions for Infectious Diseases (GSID)
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
ALVAC-HIV (vCP1521) + gp120 B/E (AIDSVAX B/E) + C gp120/MF59
(HVTN 097)
Global Solutions for Infectious Diseases (GSID)
IDT
Novartis
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Disease (NIAID)
CH505 Sequential Env: EnvSeq T/F EnvSeq 53 EnvSeq 78EnvSeq 100 Duke University
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
Clade C gp140 utilizing Chimp Ad 6 and Chimp Ad 7 vectors HIV Vaccine Trials Network (HVTN)
US Military HIV Research Program (MHRP)
National Institute of Allergy and Infectious Diseases (NIAID)
CN54gp140 (study name: X001) International AIDS Vaccine Initiative (IAVI)
Imperial College London
DNA [5 Env (clade A B AE C and D) + 1 Gag; CON-S gp120] + gp120 Env protein (clades A B AE C) adjuvanted with GLA Infectious Disease Research Institute (IDRI)
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
EN41-FPA2 (gp4-based vaccine) Sanofi Pasteur
University of Granada
Polymun Scientific
University of Surrey
PX’Therapeutics
GTU-MultiHIV Imperial College of London School of Medicine
UK Medical Research Council (UK MRC)
HIV-MAGpDNA + GENEVAX IL-12 pDNA + VSVgag+VSVenvC
(HVTN 112)
Profectus Biosciences
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
MHRP gp145 Chinese Center for Disease Control and Prevention
US Military HIV Research Program (MHRP)
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
MVA mosaic
(IPCAVD006/CrucellA002)
Crucell (Janssen)
Ragon Institute
National Institute of Allergy and Infectious Diseases (NIAID)
MVA/HIV62 National Institute of Allergy and Infectious Diseases (NIAID)
MVA62B + gp120 B/E (AIDSVAX B/E)
(HVTN 114)
GeoVax
Global Solutions For Infectious Diseases (GSID)
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
MVA-CMDR + DNA Nat-B env [HV13288] or DNA CON-S env [HV13287 or DNA Mosaic env [trivalent HV13284 HV13285 and HV13286]
(HVTN 106)
Duke University
US Military HIV Research Program (MHRP)
National Institute of Allergy and Infectious Diseases (NIAID)
p24CE1/2 DNA and p55Gag DNA plus GENEVAX IL-12 DNA Plasmid University of Washington Seattle
National Cancer Institute (NCI)
Ichor Medical Systems Inc
Althea
Profectus BioSciences Inc
National Institute of Allergy and Infectious Diseases (NIAID)
PENNVAX-G Inovio Pharmaceuticals Inc
National Institute of Allergy and Infectious Diseases (NIAID)
US Military HIV Research Program (MHRP)
PENNVAX-GP IL-12 DNA
(HVTN 098)
Inovio Pharmaceuticals Inc
National Institute of Allergy and Infectious Diseases (NIAID)
US National Institutes of Health (NIH)
Polyvalent DNA Protein HIV Vaccine (PDPHV): Env (A B C E)/Gag (C)-expressing DNA plasmids and recombinant gp120 (A B C E) protein + GLA adjuvant University of Massachussets Medical School
Infectious Disease Research Institute (IDRI)
Waisman Biomanufacturing
National Institute of Allergy and Infectious Diseases (NIAID)
SeV-G(NP) (also referred to as Sendai) International AIDS Vaccine Initiative (IAVI)
ID Pharma Co Ltd (formerly called DNAVEC Corporation)
Project San Francisco (PSF) Kigali
Kenyatta National Hospital-KAVI
St Stephen’s Centre London
Tiantian vaccinia HIV vaccine Chinese Center for Disease Control and Prevention
National Vaccine and Serum Institute China
Trimeric gp 140 protein + Alum
(IPCAVD008/CrucellA003)
Crucell (Janssen)
Beth Israel Deaconess Medical Center   Massachusetts (BIDMC)
US MilitaryHIV Research Program (MHRP)
National Institute of Allergy and Infectious Diseases (NIAID)
VICHREPOL Federal Medical and Biological Agency Russia
Ministry of Education and Science Russian Federation
Moscow Institute of Immunology
Ad26mosaic + MVAmosaic + C gp140/alum
9IPCAVD009/CrucellA004)
Crucell (Janssen)
Beth Israel Deaconess Medical Center (BIDMC)
US Military HIV Research Program (MHRP)
International AIDS Vaccine Initiative (IAVI)
National Institute of Allergy and Infectious Diseases (NIAID)
ALVAC (vCP2438) + C gp120/MF59 or C gp120/alum
(HVTN 107)
Sanofi
Novartis
Infectious Disease Research Institute (IDRI)
Bill & Melinda Gates Foundation
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
ALVAC (vCP2438) + C gp120/MF59 or C gp120/AS01B
(HVTN 113)
Sanofi
Novartis
GSK
Bill & Melinda Gates Foundation
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
DNA PT123 + C gp120/MF59 or C gp120/AS01B
(HVTN 108)
Novartis
GSK
IPPOX
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
DNA PT123 + NYVAC PT1/PT4 + C gp120/MF59 or C gp120/AS01B
(HVTN 109)
Sanofi
IPPOX Foundation
Novartis
GSK
Bill & Melinda Gates Foundation
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
NYVAC PT1/PT4 + C gp120/MF59 or C gp120/AS01B
(HVTN 109)
Sanofi
EuroVacc
Novartis
GSK
Bill & Melinda Gates Foundation
HIV Vaccine Trials Network (HVTN)
National Institute of Allergy and Infectious Diseases (NIAID)
Vacc-C5 Bionor Pharma ASA
University of Maryland
Ab Discovery/Immunobiology International AIDS Vaccine Initiative (IAVI)
b121a and b122a Indian Institute of Science
Jawaharlal Nehru Centre for Advanced Scientific Research
International AIDS Vaccine Initiative (IAVI)
Duke University
BG505 International AIDS Vaccine Initiative (IAVI)
CDV International AIDS Vaccine Initiative (IAVI)
iVSV International AIDS Vaccine Initiative (IAVI)
VSV International AIDS Vaccine Initiative (IAVI)
Malaria
(39 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
RTS,S/AS01E GSK
PATH MVI
ChAd63/MVA ME-TRAP University of Oxford
European Vaccine Initiative (EVI)
UK Medical Research Council The Gambia
Kenyan Medical Research Institute
Universite Cheikh Anta Diop Senegal
Centre National de Recherche et de Formation sur le Paludisme (CNRFP)
GMZ2 field/Alhydrogel Statens Serum Institute
Navrongo Health Research Centre
Centre National de Recherche et de Formation sur le Paludisme (CNRFP) (Burkina Faso)
London School of Hygiene and Tropical Medicine (LSHTM)
Makerere University Kampala (MUK)
Medical Research Council (The Gambia)
European Vaccine Initiative (EVI)
MSP3-LSP/AlOH African Malaria Network Trust (AMANET)
European Vaccine Initiative (EVI)
Institut Pasteur
University of Bamako
Centre National de Recherche et de Formation sur le Paludisme (CNRFP)
National Institute for Medical Research (NIMR – Tanga Centre)
ChAd63 AMA1/MVA AMA1 Southampton University Hospital
University College London
University of Oxford
Okairos/ReiThera
European Vaccine Initiative (EVI)
ChAd63 MSP1/MVA MSP1 Southampton University Hospital
University College London
University of Oxford
Okairos/ReiThera
European Vaccine Initiative (EVI)
ChAd63 RH5 +/- MVA RH5 University of Oxford
European Vaccine Initiative (EVI)
Okairos/ReiThera
GSK
Novartis
ChAd63/MVA PvDBP University of Oxford
Okairos/ReiThera
International Centre for Genetic Engineering and Biotechnology (ICGEB)
CSVAC University of Oxford
European Vaccine Initiative (EVI)
Royal College of Surgeons in Ireland (RCSI)
P27A/GLA-SE or Alhydrogel European Vaccine Initiative (EVI)
University of Lausanne
Centre Hospitalier Universitaire Vaudois (CHUV)
Ifakara Health Institute, Tanzania
PfAMA1-DiCo/GLA-SE or Alhydrogel Inserm
European Vaccine Initiative (EVI)
Biomedical Primate Research Centre BPRC (The Netherlands)
CIC BT505 Cochin Pasteur
Centre National de Recherche et de Formation sur le Paludisme
PfCelTOS FMP012/GLA-SE Walter Reed Army Institute of Research (WRAIR)
GSK
PfPEBS-LSP/AlOH Vac4All
Institut Pasteur
Sentinext Therapeutics
European Vaccine Initiative (EVI)
Centre Hospitalier Universitaire Vaudois (F.Spertini)
Pfs230D1M-EPA/Alhydrogel + Pfs25M-EPA/Alhydrogel National Institute of Allergy and Infectious Diseases (NIAID)
Pfs25-VLP/Alhydrogel Fraunhofer CMB
Accelovance
PATH MVI
PfSPZ vaccine Sanaria Inc
US Naval Medical Research Center (NMRC)
National Institute of Allergy and Infectious Diseases (NIAID)
University of Maryland Baltimore
Ifakara Health Institute Tanzania
Swiss Tropical and Public Health Institute (STPHI)
PATH MVI
PlasProtecT Griffith University
SE36/AlOH Research Foundation for Microbial Diseases of Osaka University
Centre National de Recherche et de Formation sur le Paludisme
European Vaccine Initiative (EVI)
adjuv R21 (RTS,S-derived) alone + with MeTRAP combined University of Oxford
GSK
Okairos/ReiThera
European Vaccine Initiative (EVI)
Novartis
AnAPN-1 Johns Hopkins University Medical School
PATH MVI
EBA175/Rh5 combination vaccine National Institute of Allergy and Infectious Diseases (NIAID)
JAIVAC-2 Vaccine (PfMSP-Fu24+ PfF2) formulated with adjuvant Malaria Vaccine Development Program (MVDP)
International Centre for Genetic Engineering and Biotechnology (ICGEB)
Zydus Cadila
MSP1 full length University of Heidelberg
University Hospital Heidelberg
European Vaccine Initiative (EVI)
DNA/HuAd5 or ChAd63 (encoding CS AMA1 or ME-TRAP ) in prime-boost regimen PATH MVI
US Naval Medical Research Center (NMRC)
University of Oxford
GenVec Inc
GSK
NMRC-M3V-Ad-PfCA in Adjuvant (7DW8-5) US Naval Medical Research Cente (NMRC)
Aaron Diamond AIDS Research Center
GenVec Inc
Rockefeller University
Pfs 48/45 Radboud University Nijmegen
London School of Hygiene and Tropical Medicine (LSHTM)
Gennova Biopharmaceuticals
Kilimanjaro Christian Medical College (KCMC)
Statens Serum Institut
PRIMVAC (PRIMALVAC) European Vaccine Initiative (EVI)
Inserm
PvDBPII PATH MVI
International Centre for Genetic Engineering and Biotechnology (ICGEB)
Malaria Vaccine Development Program (MVDP)
Syngene International Limited
Recombinant P. falciparum CSP-based vaccine adjuvanted with GLA-SE National Institute of Allergy and Infectious Diseases (NIAID)
Pfenex Inc
Infectious Disease Research Institute (IDRI)
Johns Hopkins Malaria Research Institute
University of Maryland Baltimore
Recombinant P. vivax CSP-based Vaccine Protein Potential LLC
National Institute of Allergy and Infectious Diseases (NIAID)
RH5 (InnoMalVac) University of Oxford
EXPRES2ION BIOTECHNOLOGIES
European Vaccine Initiative (EVI)
PAMVAC (PAMCPH/PlacMalVac) University of Copenhagen
European Vaccine Initiative (EVI)
EXPRES2ION BIOTECHNOLOGIES
CMC Biologics A/S
University of Abomey-Calavi
l’Institut de Recherche pour le Développement (IRD)
Eberhard Karls Universität, Tübingen
VMP002 – second generation E. coli expressed P. vivax CSP-based vaccine Walter Reed Army Institute of Research (WRAIR)
Recombinant P. falciparum CSP Walter Reed Army Institute of Research (WRAIR)
Imperial College London
Infectious Disease Research Institute (IDRI)
3M Drug Delivery Systems
SAPN nanoparticle P. falciparum CSP Walter Reed Army Institute of Research (WRAIR)
US Department of Defence (DOD)
Alpha-O Peptides AG
Pfs25-IMX313 University of Oxford
European Vaccine Initiative (EVI)
Okairos/ReiThera
GSK
Imaxio
CSP RI conjugates PATH MVI
New York University (NYU)
Merck MSD
EBA-Rh PATH MVI
Walter and Elizabeth Hall Institute (WEHI)
Gennova
PvDBP3-5 PATH MVI
Walter and Elizabeth Hall Institute (WEHI)
Diarrhoeal diseases
(28 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
PXVX-0200 PaxVax Inc
BRV-PV Serum Institute of India
BRV-TV ChengDu Institute of Biological Products Co Ltd (CDIBP)
Instituto Butantan São Paulo
Shantha Biotech
Chemically prepared glycoconjugate National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health & Human Development
Live attenuated Vibrio cholerae strain 638 (CV638) Finlay Institute
ACE527 (aroC omp F and Omp C-based live attenuated; may include dmLT adjuvant) Johns Hopkins Bloomberg School of Public Health
PATH
Pierrel Research USA
TD Vaccines A/S
China National Biotec Group
Anti-adhesin based subunit vaccine US Naval Medical Research Center (NMRC)
PATH
ETVAX PATH
Scandinavian BioPharma
RV3_BB PATH
Murdoch University
Australian Government
Bio-Farma
Gadjah Mada University
Otago University
Royal Children’s Hospital
University of Melbourne
WHO
VirG-based live attenuated (WRSS1 WRSs3 WRSf3) Walter Reed Army Institute of Research (WRAIR)
dmLT National Institute of Allergy and Infectious Diseases (NIAID)
PATH
Tulane University
P2-VP8 recombinant subunit rotavirus
vaccine
PATH
GMMA GSK (ex-Novartis Vaccines Institute for Global Health)
GuaBA-based live attenuated (CVD1208S) University of Maryland (UMB) Baltimore
GVXN SD133 GlycoVaxyn
Inactivated trivalent Shigella whole cell PATH
Anti-adhesin-toxoid fusion (MEFA) Kansas State University (KSU)
Johns Hopkins Bloomberg School of Public health (JHBSPH)
LT-ST fusion/LTB-ST conjugate The International Enteric Vaccine Consortium (EntVac)
Global Health and Vaccination Research (GLOBVAC)
STOPENTERICS
PATH
Second-generation 1208S attenuated
Shigella vaccine expressing CF/CS
antigens and LT toxoid
Center for Vaccine Development, University of Maryland
Typhetec Prokarium
Heat stable Rotavirus Vaccine Hilleman Laboratories (Merck MSD and Wellcome Trust joint venture)
34kDa OMP National Institute of Cholera and Enteric Diseases, India
DB Fusion PATH
InvaplexAR Walter Reed Army Institute of Research (WRAIR)
OMV University of Navarra, Spain
PSSP1 International Vaccine Institute (IVI)
Synthetic glycoconjugate Institut Pasteur
Ty21a typhoid vaccine expressing Shigella LPS Protein Potential
Tuberculosis
(24 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Crucell Ad35/AERAS-402 Aeras
Crucell
H1-IC31 Statens Serum Institut
Intercell AG
H4/AERAS-404 + IC31 Aeras
Sanofi Pasteur
Statens Serum Institut
Intercell AG
H56/ AERAS-456 + IC31 Aeras
Statens Serum Institut
Intercell AG
M72 + AS01E Aeras
GSK
MVA85A / AERAS-485 Aeras
University of Oxford
Emergent BioSolutions
RUTI Archivel Farma SL
VPM1002 TuBerculosis Vaccine Initiative
Stellenbosch University, South Africa
Children’s Infectious Disease Clinical Research Unit
Vakzine Projekt Management GmbH
Ad5Ag85A McMaster University
Dar-901 Aeras
Dartmouth-Hitchcock Medical Center
H1-CAF01 Statens Serum Institut
ID93 in GLA-SE Aeras
Infectious Disease Research Institute (IDRI)
IMX-TB2 University of Oxford
Imaxio
MTBVAC01 TuBerculosis Vaccine Initiative (TBVI)
University of Zaragoza Spain
BIOFABRI
Ag85A DNA or ESAT6/Ag85A chimeric DNA vaccines Shanghai H&G Biotechnology Co Ltd
BCGIP Medicine in Need
Carbohydrate-protein conjugate vaccines Karolinska Institute
Live attenuated Mtb derivatives (AECM) Albert Einstein College of Medicine
TB-SLP Transgene SA
ISA Pharmaceuticals BV
THSTI/UD TB Vaccine Translational Health Science Technology Institute, India
University of Delhi, South Campus
HspC with TB antigens ImmunoBiology Ltd
IKEPLUS Albert Einstein College of Medicine
Live attenuated Mtb derivatives (Pasteur) Institut Pasteur
French National Institute of Health and Medical Research (Inserm)
National Center for Scientific Research (CNRS)
rBCG and T&B epitopes University of Science, Malaysia
Finlay Institute, Cuba
Kinetoplastids
(18 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
LEISH-F1 Infectious Disease Research Institute (IDRI)
LEISH-F2 Infectious Disease Research Institute (IDRI)
LEISH-F3 Infectious Disease Research Institute (IDRI)
Gennova Biopharmaceuticals
ASP-2 Kyushu University
Cruzipain National Administration of Laboratories and Institutes of Health (ANLIS)
Ministry of Health of Argentina
GP82 Universidade Federal de São Paulo
Live attenuated Trypanisoma cruzi Instituto de Patología Experimental-CONICET
Universidad Nacional de Salta Argentina
Live Trypanosoma rangeli Servicio Nacional de Chagas Córdoba Argentina
MASP University of Texas at El Paso
Tc24 Sabin Vaccine Institute
Tc52 Universidad de Buenos Aires
Helmholtz Centre for Infection Research, Germany
TcG1 Sabin Vaccine Institute
University of Texas Medical Branch
TcG2 Sabin Vaccine Institute
University of Texas Medical Branch
TcG4 Sabin Vaccine Institute
University of Texas Medical Branch
TcVac2 University of Texas Medical Branch
TSA-1 Sabin Vaccine Institute
LdNH36 with Lutzomyia sandfly antigens Sabin Vaccine Institute
LeishDNAvax Charité – Universitätsmedizin Berlin
Drugs for Neglected Diseases initiative (DNDi)
Indian Institute of Chemical Biology
Institut Pasteur de Tunis
London School of Hygiene and Tropical Medicine (LSHTM)
MOLOGEN AG
Rajendra Memorial Research Institute of Medical Sciences, India
The Hebrew University of Jerusalem
Helminth infections
(15 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Bilhvax (Sh-GST28) Eurogentec
French National Institute of Health and Medical Research (Inserm)
Institut Pasteur
NaAPR-1 Sabin Vaccine Institute PDP
NaGST-1 Sabin Vaccine Institute PDP
Sm14 (Schisto) Brazillian Innovation Agency
Oswaldo Cruz Foundation
Sm28-GSTe Institute Pasteur
Sm28-TPIe Harvard School of Public Health
Sm97 paramyosin Cornell University
Case Western Reserve University
National Institute of Allergy and Infectious Diseases (NIAID)
SmTSP-2c (tetraspanin D) Sabin Vaccine Institute PDP
Ov-103 The Onchocerciasis Vaccine for Africa (TOVA) Initiative
Sabin Vaccine Institute
Ov-RAL-2 The Onchocerciasis Vaccine for Africa (TOVA) Initiative
Sabin Vaccine Institute
CT-SOD State University of New York
Oswaldo Cruz Foundation
Brown University
rSm-p80 Texas Tech University
Sm23 Johns Hopkins
Harvard University
Sm29 Oswaldo Cruz Foundation
The George Washington University
Sm-p80-VR1020 Texas Tech University
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
O:2-TT + Vi-TT (Bivalent conjugate enteric fever vaccine) US National Institutes of Health (NIH)
Lanzhou Institute of Biological Products
Vi-CRM197 (conjugate typhoid vaccine) Novartis Vaccines Institute for Global Health
Biological E
WTO5 Microscience Ltd
CVD 1902 + CVD 909 (Live oral bivalent enteric fever vaccine) University of Maryland Center for Vaccine Development
Bharat biotech
Vi-DT (conjugate typhoid vaccine) International Vaccine Institute (IVI)
US National Institutes of Health (NIH)
PT BioFarma
Bivalent conjugate (O:45-CRM197
and O:9-CRM197)
Novartis Vaccines Institute for Global Health
COPS: FliC conjugates using CVD 1925 and CVD 1943 reagent strains University of Massachusetts Boston (UMB)
Bharat Biotech
Wellcome Trust
CVD 1931 and CVD 1944 (Bivalent live oral NTS vaccine) University of Maryland Center for Vaccine Development
NTS-GMMA GSK (ex-Novartis Vaccines Institute for Global Health)
O:4-TT US National Institutes of Health (NIH)
Lanzhou Institute of Biological Products Co Ltd
OmpD University of Birmingham
O:2-CRM197 + Vi-CRM197 (Bivalent conjugate enteric fever vaccine) Novartis Vaccines Institute for Global Health
Biological E
O:2-DT + Vi-DT (Bivalent conjugate enteric fever vaccine) International Vaccine Institute (IVI)
Bacterial Pneumonia & Meningitis
(11 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
GSK2189242A PATH
GSK
MRC labs
London School of Hygiene and Tropical Medicine (LSHTM)
PhtD/pneumolysoid/PcpA common protein vaccine Sanofi Pasteur
Pneumococcal whole cell vaccine PATH
Boston Children’s Hospital
V114 Merck MSD
Serum Institute of India
Live Recombinant Attenuated Salmonella Vaccine Arizona State University
Trivalent protein Genocea Biosciences
Liverpool School of Tropical Medicine (LSTM)
Low-cost thermostable ACWXY meningococcal conjugate vaccine PATH
Serum Institute of India
PneuGEM Mucosis BV
Radboud University Nijmegen Medical Centre
Pneumococcal 13-valent conjugate vaccine SinoVac Biotech Ltd
Low-cost pneumococcal conjugate vaccine PATH
Serum Institute of India
Novel conjugation technology using common protein carriers Multiple Antigen Presenting System (MAPS) PATH
Affinivax Inc
Hepatitis C
(4 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Ad3ChNSmut1 / MVA-Nsmut in prime boost regimen National Institute of Allergy and Infectious Diseases (NIAID)
2nd generation ChAd3 Ii-NSmut / MVA Ii-Nsmut vaccine – prime boost (PEACHI consortium) GSK
University of Oxford
ReiThera
St James’ Hospital Dublin
Kantonsspital St Gallen
HCV-1 recombinant gpE1/gpE2 University of Alberta
Novartis
Delta3 Burnet Institute
Trachoma
(3 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
T cell vaccine based on dendritic cell immunoprotemics Pan-Provincial Vaccine Enterprise Inc (PREVENT)
University of British Columbia
British Columbia Centre for Disease Control
rMOMP vaccine National Institute of Allergy and Infectious Diseases (NIAID)
University of California, Irvine
Identification of new vaccine constructs against Chlamydia trachomatis Prokarium
Imperial College London
Rheumatic fever
(2 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
A vaccine for group A streptococcal
to prevent rheumatic heart disease
Institute for Glycomics, Griffith University
StreptInCor (vaccine candidate peptide) University of São Paulo
Buruli Ulcer
(1 candidate)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
TMX 201 adjuvant-based Buruli ulcer vaccine Swiss TPH
Telormedix SA

Drugs

142
products in
the pipeline
TB drugs
maralia drugs
HIV drugs
kinetoplastids drugs
Helminth Infections drugs
hip_C drugs
Diarrhoeal Diseases drugs
dengue drugs
Cryptococcal Meningitis drugs
Leprosy drugs
Tuberculosis
(51 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
PaMZ (PA-824/ Moxifloxacin/ Pyrazinamide) TB Alliance
AZD5847 National Institute of Allergy and Infectious Diseases (NIAID)
AstraZeneca
PNU-100480 (Sutezolid) Sequella Inc
SQ-109 National Institute of Allergy and Infectious Diseases (NIAID)
Sequella Inc
CB2009 Canopus BioPharma Inc
CB3900 Canopus BioPharma Inc
TBA-354 (nitroimidazole) TB Alliance
BDM-I BioDiem Ltd
CPZEN45 Microbial Chemistry Research Foundation
National Institute of Allergy and Infectious Diseases (NIAID)
Eli Lilly and Company
Infectious Disease Research Institute (IDRI)
YourEncore
PBTZ 169 Innovative Medicines for Tuberculosis (iM4TB)
EPFL:”École polytechnique fédérale de Lausanne
Q203 Qurient Therapeutics
SQ-609 National Institute of Allergy and Infectious Diseases (NIAID)
Sequella Inc
SQ-641 (capuramycin) National Institute of Allergy and Infectious Diseases (NIAID)
Sequella Inc
TBI-166 Institute of Materia Medica
Unnamed Okairos TB drug Okairos AG
SND-159 University of Medicine and Dentistry of New Jersey
Snowdon Inc
ATP Synthase Inhibitors TB Alliance
California Institute for Biomedical Research
Azaindoles TB Alliance
Bacterial PPMO (RNA-based Therapeutic Candidates for XDR-TB) Karolinska Institute
Sarepta Therapeutics (formerly AVI BioPharma)
Bismuth-thiols Microbion Corporation
Cyclopeptides Sanofi
TB Alliance
DF-152 Dafra Pharma International
Diarylquinolines University of Auckland
Janssen
TB Alliance
Energy metabolism inhibitors University of Pennsylvania
TB Alliance
EsxA secretion inhibitors (BBH7 and BTP15) More Medicines for TB Consortium (MM4TB): EPFL Global Health Institute
University of Cologne
Vichem Chemie Research Ltd
Semmelweis University
Ethionamide enhancer molecules Bioversys AG
Fungal (actinomycete) metabolites Mycosnthetix Inc
University of Illinois at Chicago
Hesed 1000 Ensoltek Co Ltd
Indazoles GSK
TB Alliance
InhA Inhibitors GSK
TB Alliance
Inhibitors of isoprenoid biosynthesis Infectious Disease Research Institute (IDRI)
Colorado State University
Eli Lilly and Company
LeuRS inhibitors GSK
Anacor Pharmaceuticals
Macrolides TB Alliance
Sanofi
Malate synthase inhibitors Texas A&M University
Menaquinone biosynthesis inhibitors Eli Lilly and Company
MmpL3 inhibitors TB Alliance
POA Prodrugs Yonsei University
TB Alliance
Radezolid Rib-X Pharmaceuticals
RNA polymerase inhibitors Rutgers University
TB Alliance
SCAR – Ruthenium (II) phosphine/diimine/picolinate complexes: Inorganic compounds as agents against tuberculosis FAPESP SÂO PAULO RESEARCH FOUNDATION
Spectinamides St Jude Children’s Research Hospital
University of Tennessee Health Science Center
Colorado State University
University of Zurich
Microbiotix Inc
SPR-113 International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi
Thiophene Carboxamides Calibr Calafornia Institute for Biomedical Research
TB Alliance
TL1 Inhibitors Sequella Inc
Tryptanthrins Korea Research Institute of Chemical Technology
Yonsei University
Unnamed Achillion TB drug Achillion Pharmaceuticals Inc
Unnamed Anacor TB drug (1) Anacor Pharmaceuticals
Unnamed Anacor TB drug (2) Anacor Pharmaceuticals
Unnamed Fit Biotech Oyj TB drug Fit Biotech Oyj
Unnamed Medisyn TB drug Medisyn Technologies Inc
Ureas TB Alliance
Sanofi
Malaria
(45 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Artemether spray; ArTiMist Eastland Medical Systems Ltd
HC Berlin Pharma AG
ProtoPharma Limited
Dihydroartemisinin/Piperaquine (DHA-PQP) Paediatric Sigma Tau Group
Medicines for Malaria Venture (MMV)
Intra-rectal Artesunate WHO Special Programme for Research and Training in Tropical Diseases (TDR)
Medicines for Malaria Venture (MMV)
Pyramax Paediatric (Pyronaridine/Artesunate) Medicines for Malaria Venture (MMV)
Shin Poong Pharmaceuticals
Tafenoquine GSK
Medicines for Malaria Venture (MMV)
Walter Reed Army Institute of Research (WRAIR)
DSM265 Medicines for Malaria Venture (MMV)
University of Texas Southwestern Medical Center
University of Washington
Monash University
Takeda Pharmaceutical Co
US National Institutes of Health (NIH)
Ferroquine (SSR97193) Sanofi
Fosmidomycin/Piperaquine Jomaa Pharma GmbH
GNF156 (KAF156) Genomics Institute of the Novartis Research Foundation
Medicines for Malaria Venture (MMV)
Novartis
NITD 609 (KAE 609; Cipargamin) Medicines for Malaria Venture (MMV)
Novartis Institute for Tropical Diseases
OZ439/Ferroquine (FQ) Medicines for Malaria Venture (MMV)
Sanofi
OZ439/Piperaquine; PQP Medicines for Malaria Venture (MMV)
Sanofi
ACT451840 Actelion Pharmaceuticals
Aminopyrdinel; MMV390048; MMV048 University of Cape Town
Swiss Tropical and Public Health Institute
Monash University
Medicines for Malaria Venture (MMV)
The Technology Innovation Agency, South Africa
CDRI 97/78 Central Drug Research Institute, India
Ipca Laboratories Ltd
CDRI 99/411 Central Drug Research Institute, India
Ipca Laboratories Ltd
DDD498 University of Dundee
Medicines for Malaria Venture (MMV)
Merck Serono
GSK030 GSK
Medicines for Malaria Venture (MMV)
Histone deacetylase (HDAC) inhibitor; LMK235 Heinrich Heine University
Eskitis Institute for Drug Discovery
University of California, San Diego
Eberhard Karls Universität, Tübingen
JPC-2997 Army Malaria Institute, Australia
University of Miami
Jacobus Pharmaceutical Company
MMV253 AstraZeneca
Medicines for Malaria Venture (MMV)
NPC1161B University of Mississippi
P218 Medicines for Malaria Venture (MMV)
National Center for Genetic Engineering and Biotechnology (BIOTEC), Thailand
Monash University
Liverpool School of Tropical Medicine (LSTM)
Pyrazoles 21A092; PA21A092 Drexel University
University of Washington
Medicines for Malaria Venture (MMV)
Quinolones; ELQ-300; P4Q-391; Pro-drug ELQ-337 University of South Florida
Oregon Health and Science University
Drexel University
Monash University
Medicines for Malaria Venture (MMV)
Liverpool School of Tropical Medicine, (LSTM)
St. Jude Children’s Research Hospital
Reversed chloroquine molecules (RCQ) DesignMedix Inc
Portland State University
SJ733 St. Jude Children’s Research Hospital
Rutgers University
University of California, San Francisco
Medicines for Malaria Venture (MMV)
Eisai Co Ltd
Acridones DesignMedix Inc
Portland State University
ACT213615 Actelion Pharmaceuticals
Amino-alcohols Merck Serono
Medicines for Malaria Venture (MMV)
Aminopyridines University of Cape Town
Swiss Tropical and Public Health Institute
Monash University
Medicines for Malaria Venture (MMV)
DHODH inhibitors (analogues of DSM265) University of Texas Southwestern Medical Center
University of Washington
Medicines for Malaria Venture (MMV)
Monash University
Diversity oriented synthesis (DOS) library lead (ML238) Broad Institute
DPAP inhibitors (ML4118S) Stanford University
University of California, Berkeley
dUTPase inhibitors University of York
University of Dundee
Medvir
GSK 3 Projects GSK
Medicines for Malaria Venture (MMV)
Novartis series lead optimization (imidazopyrazines) Genomics Institute of the Novartis Research Foundation
Swiss Tropical and Public Health Institute
Biomedical Primate Research Centre
Medicines for Malaria Venture (MMV)
Open Source Drug Discovery (OSM Series 4) University of Sydney
Medicines for Malaria Venture (MMV)
Oxaboroles (AN3661) Anacor Pharmaceuticals Inc
Medicines for Malaria Venture (MMV)
University of California, San Francisco
GSK
Pf NDH2 inhibitors (SL-2-64 CK-2-68 CK-2-25) Liverpool School of Tropical Medicine (LSTM)
University of Liverpool
Pf NMT inhibitors Imperial College of London
UK MRC National Institute for Medical Research
University of Nottingham
University of York
Pfizer Inc
Protein Kinase inhibitors Monash University
Medicines for Malaria Venture (MMV)
Sanofi orthologue leads Sanofi
Medicines for Malaria Venture (MMV)
St. Jude/Rutgers Antimalarials   (Dihydropyridines) St. Jude Children’s Research Hospital
Rutgers University
University of South Florida
St. Jude/Rutgers Antimalarials (Diaminonaphthoquinones) St. Jude Children’s Research Hospital
Rutgers University
University of South Florida
HIV
(19 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
LPV/r pellets with dual NRTI FDC Drugs for Neglected Diseases initiative (DNDi)
Cipla Ltd
UNITAID
National Department of Health, South Africa
University of Nairobi
KEMRI Walter Reed Project
Dapivirine ring International Partnership for Microbicides (IPM)
Janssen Sciences Ireland UC (previously Tibotec)
Long-acting injectable formulation of rilpivirine (TMC278) as PrEP PATH
Janssen
HIV Vaccine Trials Network (HVTN)
NIH
Two ‘4-in-1′ LPV/r-based Fixed-Dose Combinations Drugs for Neglected Diseases initiative (DNDi)
Dapivirine gel International Partnership for Microbicides (IPM)
Janssen Sciences Ireland UC (previously Tibotec)
Tenofovir gel CONRAD
Centre for the AIDS Programme of Research in South Africa
US Agency for International Development (USAID)
VivaGel National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health & Human Development
Star Pharma
Amphora National Institute of Allergy and Infectious Diseases (NIAID)
EvoFem
Dapivirine film International Partnership for Microbicides (IPM)
Janssen Sciences Ireland UC (previously Tibotec)
Dapivirine-darunavir gel International Partnership for Microbicides (IPM)
Janssen Sciences Ireland UC (previously Tibotec)
Maraviroc ring and dapivirine-maraviroc ring International Partnership for Microbicides (IPM)
ViiV healthcare
Maraviroc vaginal and rectal gels International Partnership for Microbicides (IPM)
ViiV healthcare
MZC/PC-1005 Gel (MIV-150 + zinc acetate + carrageenan) Population Council
Dapivirine rectal gel International Partnership for Microbicides (IPM)
Janssen Sciences Ireland UC (previously Tibotec)
DS001 (L167) DS004 (L872) DS005 (L882) International Partnership for Microbicides (IPM)
Merck MSD
DS003 (BMS793) vaginal tablet and vaginal ring International Partnership for Microbicides (IPM)
BMS
DS007 (L-644 peptide) International Partnership for Microbicides (IPM)
Merck MSD
MIV-150 + Zinc + vaginal ring Population Council
Tenofovir and tenofovir/emtricitabine vaginal Tablets CONRAD
Kinetoplastids
(12 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Fexinidazole Drugs for Neglected Diseases initiative (DNDi)
HAT Platform Partners
Sanofi-Aventis
Swiss Tropical and Public Health Institute
E1224/benznidazole (combination treatment) Drugs for Neglected Diseases initiative (DNDi)
Eisai
Anfoleish Drugs for Neglected Diseases initiative (DNDi)
PECET (Program for the Study and Control of Tropical Diseases), Universidad de Antioquia Medellin Colombia
Humax Pharmaceutical, Colombia
Oxaborole SCYX-7158 Drugs for Neglected Diseases initiative (DNDi)
Anacor Pharmaceuticals Inc
Pace University
SCYNEXIS Inc
Swiss Tropical and Public Health Institute
Advinus Therapeutics
DB829 (CPD-0802) Consortium for Parasitic Drug Development
Georgia State University
The University of North Carolina at Chapel Hill
Corifungin Acea Biotech
Sandler Centre for Drug Discovery (UCSF)
CpG-D35 Drugs for Neglected Diseases initiative (DNDi)
University of Osaka
VL-2098 Drugs for Neglected Diseases initiative (DNDi)
TB Alliance
Advinus Therapeutics
Endolytics
Nitroimidazole Drugs for Neglected Diseases initiative (DNDi)
University of Auckland
TB Alliance
Monash University
Epichem
Murdoch University
Federal University of Ouro Preto (UFOP) Brazil
Institut Pasteur Korea (IPK) South Korea
Oxachagas Drugs for Neglected Diseases initiative (DNDi)
Anacor Pharmaceuticals Inc
SCYNEXIS Inc
Murdoch University
Wuxi AppTech
Sandexis
Laboratory of Microbiology Parasitology and Hygiene (LMPH), University of Antwerp
Nitroimidazole backup (VL) Drugs for Neglected Diseases initiative (DNDi)
TB Alliance
Auckland University
Laboratory of Microbiology Parasitology and Hygiene (LMPH) University of Antwerp
WuXi AppTech
Oxaleish programme   (primary lead: DNDi/Oxa-2035804) Drugs for Neglected Diseases initiative (DNDi)
Anacor Pharmaceuticals
SCYNEXIS Inc
Helminth infections
(6 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Moxidectin Pfizer Inc.
WHO/TDR
Medicines Development for Global Health
Co-Arinate FDC (Artesunate-Sulfamethoxypyrazine/Pyrimethamine) Dafra Pharma Research & Development BVBA
Oxantel pamoate Swiss TPH
University of Basel
Deuterated praziquantel analogues CoNCERT Pharmaceuticals Inc
US National Institutes of Health (NIH)
Praziquantel paediatric Astellas Pharma
Merck Serano
Swiss TPH
TI Pharma
Emodepside Bayer AG
Drugs for Neglected Diseases initiative (DNDi)
Astellas Pharma
Hepatitis C
(3 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Asunaprevir Daclatasvir Ribavirin and Pegylated Interferon Alpha-2a Bristol-Myers Squibb
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Grazoprevir/Elbasvir Merck MSD
Next-Gen HCV Combination (ABT-493 ABT-530) AbbVie
Diarrhoeal Diseases
(2 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
AKT10081 Akthelia Pharmaceuticals
AKT10082 Akthelia Pharmaceuticals
Dengue
(2 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
CB5300 Canopus BioPharma Inc
DengueCide NanoViricides Inc
Cryptococcal Meningitis
(1 candidate)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
VT-1129 Viamet pharmaceuticals
NIH Therapeutics for Rare and Neglected Diseases programme
Leprosy
(1 candidate)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Bedaquiline Janssen-Cilag
Leonard Wood Memorial
Johnson & Johnson

diagnostics

124
products in
the pipeline
TB diagnostics
maralia diagnostics
HIV diagnostics
kinetoplastids drugs
hip_C diagnostics
Buruli Ulcer diagnostics
Helminth Infections diagnostics
Leptospirosis diagnostics
Leprosy diagnostics
_bacterialM diagnostics
dengue diagnostics
Diarrhoeal Diseases diagnostics
Trachoma diagnostics
Tuberculosis
(42 candidates)
Product/Candidate name Key developers/partners Early development Late development
AV Breath Test Avisa Pharma Inc
CellScope (cell phone plus microscope) Makerere University
University of California Berkeley
University of California San Francisco
World Health Partners
C-Tb-TST Statens Serum Institut
Fluorobot ConsultASK Ltd
ASK-M
Ateknea Solutions
Genedrive Xcelris Labs Ltd
Epistem
HYDRA-1K InSilixa
InterGam Rapid Immuno Suspension Assay (IRISA-TB) Antrum Biotech
LATE PCR with Lights on/Lights Off Probes and PrimeSafe technology Stellenbosch University South Africa
Brandeis University
Hain Lifescience Gmbh
MBio multiplexed immunoasssay platform MBio Diagnostics Inc
Foundation for Innovative New Diagnostics (FIND)
TAM-TB Assay University of Munich
Swiss Tropical and Public Health Institute
NIMR-Mbeya Medical Research Center (MMRC)
TBDx system Keck Graduate Institute
Claremont BioSolutions LLC
University of Washington
PATH
Seattle & King County TB Clinic
Leardon Solutions
Ustar Biotechnologies
Urinary antigen detection (LAM) Tuberculosis Clinical Diagnostics Research Consortium
Alere
Foundation for Innovative New Diagnostics (FIND)
Loop-mediated isothermal amplification (LAMP) of DNA (TB) Eiken Chemical
Foundation for Innovative New Diagnostics (FIND)
Aeonose The eNose Compnay
Xpert Ultra and Xtend XDR Cepheid
Rutgers University
Alere Q TB assay Alere
BreathLink Menssana Research INC
DiagCORE STAT-Diagnostica
Enigma ML Enigma Diagnostics
EOSCAPE-TB and TB-DST Wave 80 biosciences
Prototype breathanalyzer Next Dimensions
Q-POC (Q-TB) MTBC and MDR assays QuantuMDx
Savanna RT-PCR Testing Platform Northwestern Global Health Foundation
Quidel Corporation
Antibody detection test (1st generation) Antigen Discovery Inc
Natural and Medical Sciences Institute (NMI) Tübingen
MBio Diagnostics Inc
University of Medicine and Dentistry of New Jersey (UMDNJ)
MicroMol Gmbh
Foundation for Innovative New Diagnostics (FIND)
Automated slide reader Becton Dickinson (BD)
BD MAX Becton Dickinson (BD)
Beta Lactamase Detection (GBD TB REaD POC – Enzymatic detection M. tuberculosis β-lactamase reporter assay) Global BioDiagnostics
Stanford University
Texas A&M University
Foundation for Innovative New Diagnostics (FIND)
B-SMART assay Sequella Inc
DigiportX TB MVIP + Software Consulting Gmbh
GenePOC real-time PCR assays for MTBC and resistance genotyping
(RIF/INH and FLQ)
GenePOC Inc
Handheld poin-of-care diagnostic device McMaster University
Immiprint system ProteinLogic
Immunochromatographic strip test TB Biosciences
New York University
Lonestar Owlstone
Magnetic barcode assay Massachusetts General Hospital
Novel antigen panel for lateral flow test Infectious Disease Research Institute (IDRI)
Novel reagents for serological diagnosis of tuberculosis Burnet Institute
Rapid colorimetric drug susceptibility test (MDR-XDRTB Colour Test) London School of Hygiene and Tropical Medicine
Foundation for Innovative New Diagnostics (FIND)
RDT to detect LAM Boston University
Real-time polymerase amplification MTBC assays TwistDx
London School of Hygiene and Tropical Medicine
PATH
SOMAmer-based tuberculosis (TB) biomarker assay SomaLogic Inc
Unyvero Curetis AG
Malaria
(28 candidates)
Product/Candidate name Key developers/partners Early development Late development
2DPN (2-D paper network) University of Washington
NanoMal malaria assay (Q-POC) NanoMal Consortium (QuantuMDx)
St. George’s University
The Karolinska Insititute
Tubingen University
Nucleic acid lateral flow immunoassays (NALFIA) – DIAGMAL Consortium Koninklijk Instituut voor de Tropen (KIT)
Forsite Diagnostics Ltd
Q-Bioanalytic GmbH
Global Innovation Network Oy
Parasight (2nd generation) Sight Diagnostics Ltd
Rapid Assessment of Malaria (RAM) Device Disease Diagnostic Group LLC
Case Western Reserve University
Urine Malaria Test Johns Hopkins University
Fyodor BioTechnologies
A better tool to identify P. vivax infections/P. vivax serology Foundation for Innovative New Diagnostics (FIND)
Walter & Eliza Hall Institute
Fundaçao do Medican Tropical
PNG Institute of Medical Research
Ehime University
Queensland Institute of Medical Research
University of Melbourne
P. falciparum infection detection test (Improved highly sensitive RDTs for P falciparum) Foundation for Innovative New Diagnostics (FIND)
Centers for Disease Control and Prevention (CDC)
Hospital for Tropical Diseases in London (UK)
Institut Pasteur du Cambodge (Cambodia)
Microcoat GmbH (Germany)
PATH (USA)
Queensland Institute for Medical Research/AMI (Australia)
Université Cheikh Anta Diop   (Senegal)
Universidad Peruana Cayetano Heredia (Peru)
ZeptoMetrix (USA)
ADCIA 2120 hematology system Siemens
Amplino Scout Amplino BV
Cell-phone based microscopy Boston University
CellScope (cell phone plus microscope) CellScope
University of California Berkeley
Computer-assisted slide reading Hydas World Health
DIAMETER infection detection test PATH
Electric impedance microflow cytometry Massachusetts Institute of Technology
Carnegie Mellon University
Foldscope Stanford University
University of California Berkeley
G6PD deficiency diagnostic PATH
GSK
High throughput LAMP Eiken Chemical
Foundation for Innovative New Diagnostics (FIND)
Hospital for Tropical Diseases
Kelch13 blood test Mahidol-Oxford Tropical Medicine Research Unit
LUCAS Holomic LLC
University of California Los Angeles
Malaria Pf/Pv Detect InBios International Inc
Microfluidic modeling University of Washington
Paper microfluidic cartridge with acridine orange staining Intellectual Ventures Lab
University of Washington
Ring-stage survival assay (RSA) Institut Pasteur du Cambodia
US National Institutes of Health (NIH)
Single nucleotide polymorphism (SNP) genotyping Broad Institute
Spectraphone QuantaSpec Inc
SpectraWave and SpectraNet Claro Scientific LLC
VCS technology Beckman Coulter
University College Hospital
HIV
(18 candidates)
Product/Candidate name Key developers/partners Early development Late development
Liat Analyzer (COBAS Liat System ) Iquum Roche Molecular Diagnostics
LYNX HIV p24 antigen assay Northwestern Global Health Foundation
Quidel Corporation
Mbio CD4 system Mbio Inc
Merck Millipore Muse Auto CD4/C4% system Merck MSD
Mobile microfluidic immunoassay (mChip) ColumbiaUniversity
Amsterdam University Medical Center
Opko Diagnostics
Rwanda-Zambia HIV Research Group
PanNAT Platform (Qualitative HIV assay) Micronics Inc
POC rapid RT-PCR testing platform (NWGHF Savanna Viral Load Test and Platform) Northwestern Global Health Foundation (NWGHF)
Quidel Corporation
Visitect CD4/Burnet Institute CD4 Initiative Burnet Institute
Massachusetts General Hospital
Partners AIDS Research Center
Omega Diagnostics
FlashOne (A rapid portable HIV detection and monitoring system for resource limited settings) Thermal Gradient
Rapid test for recent HIV infection Immunetics Inc
CD4+ T-lymphocyte test Imperial College of London School of Medicine
PATH
PortaScience
University of Washington
EOSCAPE-NAT HIV Rapid RNA Assay system WAVE 80 Biosciences
Genedrive Epistem Ltd
Gene-RADAR Platform Nanobiosym Diagnostics
Non-instrumented nucleic acid amplification (NINA) platform PATH
RT CPA HIV-1 Viral Load Test Ustar Biotechnologies
University of Victoria
Truelab Real Time micro PCR System Molbio Diagnostics (Tulip Group-Bigtec laboratories partnership)
Viral load assay using BART (Bioluminesent Assay in Real-Time) technology Lumora Ltd
Kinetoplastids
(12 candidates)
Product/Candidate name Key developers/partners Early development Late development
LAMP Test Foundation for Innovative New Diagnostics (FIND)
Murdoch University
Obihiro University
Eiken Chemical Co Ltd
ELISA test for Leishmania antigens Foundation for Innovative New Diagnostics (FIND)
Drugs for Neglected Diseases initiative (DNDi)
International Centre for Diarrhoeal Disease Research Bangladesh (ICDDR,b)
Kenya Medical Research Institute (KEMRI)
LAMP Test Foundation for Innovative New Diagnostics (FIND)
Royal Tropical Institute, Netherlands
Wellcome Trust
Sanger Institute
TiPharma
Eiken Chemical Co Ltd
LAMP Test Infectious Disease Research Institute (IDRI)
WHO Special Programme for Research and Training in Tropical Diseases
Chunap (Chagas urine nanoparticle test) Johns Hopkins University
IDRI diagnostic next generation Foundation for Innovative New Diagnostics (FIND)
INGEBI/CONICET
London School of Hygiene and Tropical Medicine
Pontificia Universidad Javeriana and Universidad de los Andes
Eiken Chemical Co
24-kDa fusion protein ELISA Instituto Nacional de Laboratorios de Salud
Universitat de Barcelona
Universidade Federal de Goiás
University of Giessen
Electrochemical impedance spectroscopy Oswaldo Cruz Foundation
Universidade Federal de Pernambuco
PATH Chagas Immunochromatographic Strip Test (ICS) PATH
lateral-flow RDT (2nd generation) Foundation for Innovative New Diagnostics (FIND) Standard Diagnostics
DPP Leishmaniasis RDT Infectious Disease Research Institute (IDRI)
Chembio Diagnostics Systems Inc.
QuantiFERON-Leishmania Banaras Hindu University
Hepatitis C
(10 candidates)
Product/Candidate name Key developers/partners Early development Late development
Alere Q (HCV-RNA) Alere
ASSURED-chip: an accurate affordable and rapid microfluidics-based diagnosis of Hepatitis-C virus Biyani Girls College (BGC)
Genedrive (HCV qual) Epistem Ltd
Institut Pasteur
GeneXpert (HCV-RNA) Cepheid
HCV LAMP assay All India Institute of Medical Sciences
Islamic Azad University, Iran
PanNAT platform (Qualitative HCV assay) Micronics Inc
Truelab PCR (HCV-RNA) Molbio Diagnostics Pvt Ltd (A Tulip Group – Bigtec labs partnership)
POC microfluidic diagnostic system Daktari Diagnostics
EOSCAPE-HCV RNA Wave 80 biosciences
RT CPA (HCV-RNA) Ustar Biotechnologies
University of Victoria
Buruli Ulcer
(3 candidates)
Product/Candidate name Key developers/partners Early development Late development
LAMP assay Foundation for Innovative New Diagnostics (FIND)
Noguchi Memorial Institute for Medical Research
Mycolactone detection by thin layer chromatography (TLC) Foundation for Innovative New Diagnostics (FIND)
WHO
Harvard University
Protein antigen capture assay Foundation for Innovative New Diagnostics (FIND)
Swiss Tropical and Public Health Institute
Standard Diagnostics (SD-Alere)
Helminth infections
(3 candidates)
Product/Candidate name Key developers/partners Early development Late development
Up-converting phosphore technology lateral flow assay (UCP-LF strop) Leiden University Medical Center
Ampath Laboratories
Filaria Detect IgG4 ELISA InBios
Ov16/Wb123 biplex rapid test PATH
US National Institutes of Health (NIH)
Standard Diagnostic (SD-Alere)
Leptospirosis
(2 candidates)
Product/Candidate name Key developers/partners Early development Late development
New Vertical Flow RDT for serodiagnosis of Leptospirosis Institut Pasteur
Complete DPP Test for Human Leptospirosis Chembio Diagnostics Systems Inc
Weill Medical College Cornell University
Oswaldo Cruz
Leprosy
(2 candidates)
Product/Candidate name Key developers/partners Early development Late development
Leprosy next generation Infectious Disease Research Institute (IDRI)
OrangeLife
A test combining an antibody-based assay and a T-cell assay into one field test Leiden University Medical Center
Bacterial Pneumonia & Meningitis
(1 candidate)
Product/Candidate name Key developers/partners Early development Late development
Paper-based microfluidic POC device University of Texas at El Paso
Dengue
(1 candidate)
Product/Candidate name Key developers/partners Early development Late development
Liat dengue assay IQuum Inc
Diarrhoeal Diseases
(1 candidate)
Product/Candidate name Key developers/partners Early development Late development
Multiplex fluorescence optofluidic microscopy for diagnosis of enteric parasites California Institute of Technology
Trachoma
(1 candidate)
Product/Candidate name Key developers/partners Early development Late development
Antibody assay for trachoma Centers for Disease Control and Prevention (CDC)

Vector Control Products

16
products in
the pipeline
maralia VCP

Malaria

dengue VCP

Tuberculosis

kinetoplastids VCP

HIV/AIDS

Malaria
(12 candidates)
Product/Candidate name Key developers/partners Early development Late development
Olyset Duo (a bi-treated net based on permethrin and pyriproxyfen) Sumitomo Chemical
Innovative Vector Control Consortium (IVCC)
A novel bed net with synergist and IRS formulation. London School of Hygiene and Tropical Medicine (LSHTM)
Chlorfenapyr-based IRS formulation BASF
Innovative Vector Control Consortium (IVCC)
LLIN combination 1 BASF
Innovative Vector Control Consortium (IVCC)
MCD Project In2Care
Biogents AG
CTF200
Ifakara Health Institute, Tanzania
Penn State University
Sumitomo Active ingredient library screening
(IVCC new active ingredient 2)
Innovative Vector Control Consortium (IVCC)
Sumitomo Chemical
Syngenta Active ingredient library screening
(IVCC new active ingredient 3)
Innovative Vector Control Consortium (IVCC)
Syngenta
Bayer Discovery Platform
(IVCC new active ingredient 1)
Innovative Vector Control Consortium (IVCC)
Bayer AG
Crop protection development compound Innovative Vector Control Consortium (IVCC)
Agircultural AI review Innovative Vector Control Consortium (IVCC)
LLIN combination 2 Innovative Vector Control Consortium (IVCC)
LLIRS formulation Innovative Vector Control Consortium (IVCC)
Dengue
(2 candidates)
Product/Candidate name Key developers/partners Early development Late development
RIDL-Sterile Insect Technique Oxitec Ltd
Wolbachia-infected mosquitoes Monash Univresity
Oswaldo Cruz Foundation (FIOCRUZ)
University of Melbourne
University of Wisconsin
James Cook University
University of California, Davis
Oxford University Clinical Research Unit, Vietnam
Kinetoplastids
(2 candidates)
Product/Candidate name Key developers/partners Early development Late development
Genetic modification of a tsetse fly gut bacterium blocking parasite proteins Swansea University
Identification of different chemical blends to repel tsetse flies Université des Montagnes

This is the first comprehensive global picture of the neglected disease R&D pipeline since 2012. It looks at 34 of the 35 neglected diseases within the scope of G-FINDER survey (Ebola is not included), covering all product categories including vector control products, and all stages of research from early stage R&D through to product registration. The data is the result of a comprehensive review of the neglected disease R&D landscape conducted by Policy Cures in late 2015, and is presented as a snapshot of the pipeline as at October 2015. For details on the methodology behind this review please see the bottom of the home page; for a quick overview of the diseases and associated products covered in this pipeline you can view the R&D matrix here.

Policy Cures Research Logo, Brisbane Street, email info[at]policycuresresearch.org